Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18153428 | 0.86 | MAPK14 (0.36) | MAPK14KHKADORA2AADORA1KDM4E | |
| SCHEMBL29654262 | 0.86 | ALDH1A1 (0.31) | KHKALDH1A1HPGDKMT2A | |
| SCHEMBL18128520 | 0.86 | ALDH1A1 (0.31) | KHKALDH1A1HPGDKMT2A | |
| SCHEMBL25295905 | 0.79 | KDM4E (0.38) | MAPK14KHKADORA2AADORA1KDM4E | |
| SCHEMBL18128716 | 0.75 | KDM4E (0.31) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL29876162 | 0.75 | KDM4E (0.31) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL18153473 | 0.75 | KRAS (0.39) | KDM4EMAPT | |
| SCHEMBL31521270 | 0.74 | KHK (0.33) | KHKADORA2AADORA1ALDH1A1 | |
| SCHEMBL19104274 | 0.74 | KDM4E (0.30) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL25987673 | 0.73 | HTT (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283462-B1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3283462-B1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10428064-B2 | Fused-tricyclic inhibitors of KRAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180086753-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-03-29 | — | — | US | disclosed |
| US-20180086753-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-03-29 | — | — | US | disclosed |
| EP-3283462-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168540-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168540-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428064-B2 | Fused-tricyclic inhibitors of KRAS and methods of use thereof | KRAS, NRAS, HRAS | MAPK14 1148/4885KHK 3927/4885ADORA2A 2742/4885 |
| US-20180086753-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MAPK14 1148/4885KHK 3927/4885ADORA2A 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.